Overview: Another Actos user has filed a lawsuit alleging that the drug’s manufacturer, Takeda Pharmaceuticals, failed to warn about dangerous side effects associated with the Type 1 diabetes drug. Plaintiff Robert Salinas filed a lawsuit alleging Actos failed to warn about the risk of bladder cancer in the Circuit Court of Cook County, Illinois.
- Takeda is facing thousands of lawsuits alleging Actos caused bladder cancer
- Many cases have been filed into the MDL currently underway in the U.S. District Court for the Western District of Louisiana
- The FDA has warned that taking Actos for one year could significantly increase the risk of bladder cancer
Product: Actos (pioglitazone)
Manufacturer: Takeda Pharmaceutical
Side Effects & Complications
- Bladder cancer
- Heart attacks
- Congestive heart failure
Lawsuit Alleges Actos Caused Bladder Cancer
Mr. Salinas’ lawsuit claims that he developed bladder cancer after taking the drug in 2004. He was diagnosed with the bladder cancer in 2008, at which point he stopped taking Actos. The lawsuit alleges that he could not have been aware that his cancer was related to his diabetes medication until he learned that the drug was pulled off the shelves overseas. He is suing for a number of damages that he had to suffer as a result of allegedly negligent and wrongful actions on the part of the Defendants. Salinas filed the lawsuit on January 2nd 2013.
Unlike this case, most Actos lawsuits have been filed in federal court as part of the multidistrict litigation known as In Re: Actos (Pioglitazone) Products Liability Litigation (MDL No. 6:11-md-2299). Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiff’s Steering Committee in the litigation.
Actos was approved in 1999 as a treatment for Type 2 diabetes. It is part of the thiazolidinedione drug class, which also includes the medication Avandia. Due to mounting evidence linking the medication to bladder cancer, the drug has come under scrutiny and thousands of lawsuits have been filed over injuries alleged by the drug. In July 2011, use of the drug was suspended in France and Germany because of its association with bladder cancer. At around the same time, the U.S. Food and Drug Administration announced that the warning label would be updated to mention the increased risk of bladder cancer, which appears to become significant after one year of use.